Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

BCR fused ABL kinase is the critical driving oncogene for chronic myeloid leukemia (CML) and has been extensively studied as the drug discovery target in the past decade. The successful introduction of tyrosine kinase inhibitors (TKI) such as Imatinib, Dasatinib and Bosutinib has greatly improved th...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Cancer Biol Ther
Główni autorzy: Wu, Jiaxin, Wang, Aoli, Li, Xixiang, Chen, Cheng, Qi, Ziping, Hu, Chen, Wang, Wenliang, Wu, Hong, Huang, Tao, Zhao, Ming, Wang, Wenchao, Hu, Zhenquan, Liu, Qingwang, Wang, Beilei, Wang, Li, Li, Lili, Ge, Jian, Ren, Tao, Xia, Ruixiang, Liu, Jing, Liu, Qingsong
Format: Artigo
Język:Inglês
Wydane: Taylor & Francis 2019
Hasła przedmiotowe:
Research Paper
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606039/
https://ncbi.nlm.nih.gov/pubmed/30894066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1579958
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy